维普期刊资源整合服务平台（V6.5）

46篇 您的检索式：作者名="Kuti C"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobaetam in patients with complicat- ed intra-abdominal infection显示文摘	Li C Kuti JL Nightingale CH	2005	J Antimicrob Chemother2005，56，2：	1
2	Haploinsufficiency for Pten and Serotonin transporter cooperatively influences brain size and social behavior 显示文摘	Page DT Kuti O J Prestia C	2009	Proc Natl Acad Sci U S A2009，106，6：	1
3	Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli,klebsiella pneumoniae,acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program:the OPTAMA Program,South America 2002显示文摘	KIFFER C R MENDES C KUTI J L	2004	Diagn Microbiol Infect Dis2004，49，2：	1
4	Optimising dosing strategies of antibacterials utilising pharmacodynamic principles:impact on the development of resistance显示文摘	Young L S Kuti J L	2006	Drugs2006，66，1：	1
5	Cost-Effective Approaches to the treatment of community-acquired pneumonia in the era of resistance显示文摘	KUTI J L CAPITANO C NICOLAU D P	2002	Phermocoeconomics2002，20，8：	1
6	Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients显示文摘	Li C Kuti JL Nightingale CH		0，，10：	1
7	Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients显示文摘	Du X Li C Kuti JL		0，，01：	1
8	Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem显示文摘	KUTI J L HOROWITZ S NIGHTINGALE C H	2005	Pharmacotherapy2005，25，7：	1
9	Optimal Dosing of Piperacil lin-Tazobactam for the Treatment of Pseudomonas aeruginosa In- fections:Prolonged or Continuous Infusion显示文摘	Kim A Sutherland C A Kuti J L	2007	Pharmacotherapy2007，27，11：	1
10	Hypoglycaemic elect of Opuntia lindheimeri Englem in a diabetic pig model显示文摘	Laurenz J C Collier C C Kuti J O	2003	Phytother Res2003，17，1：	1
11	Pharmacodynamie comparisons of antimierobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002 显示文摘	KIFFER C R MENDES C KUTI J L	2004	Diagn Microbiol Infect Dis2004，49，2：	1
12	Optimizing Pharmacodynamic Target Attainment using the MYSTIC Antibiogram: data collected in North America in 2002 显示文摘	KUTI J L NIGHTINGALE C II NICOLAU D P	2004	Antimicrob Agents Chemother2004，48，7：	1
13	Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy in skin and soft tissue infections:a report from the OPTAMA Program 显示文摘	ONG C T KUTI J L NICOLAU D P	2005	Surg Infect2005，6，4：	1
14	Population pharmaco- kinetic analysis and dosing regimen optimization of meropenem in adult patients 显示文摘	Li C Kuti JL Nightingale CH	2006	J Clin Pharmacol2006，46，10：	1
15	Multiple repeats of a promoter segment causes transcription factor autoregulation in red apples显示文摘	ESPLEY R V BRENDOLISE C CHAGNE D KUTI'Y-AMMA S GREEN S VOLZ R PUTFERILL J SCHOUTEN H J GARDINER S E HELLENS R P ALLAN A C	2009	Plant Cell2009，21，1：	1
16	Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States 显示文摘	KOOMANACHAI P BULIK C C KUTI J L	2010	Clin Ther2010，32，4：	1
17	Clinical pharmacodynamics ofmeropenem in patients with lower respiratory tract infections 显示文摘	Li C Du X Kuti JL	2007	Antimicrob Agents Chemother2007，51，5：	1
18	Population pharmacokinet- ics and pharmacodynamics of meropenem in pediatric patients 显示文摘	Du X Li C Kuti J L	2006	J Clin Pharmacol2006，46，1：	1
19	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections显示文摘	LI C DU X KUTI JL	2007	AntimicrobAgents Chemother2007，51，5：	1
20	Hypoglycaemic effect of Opuntia lindheimeri Englem in a diabetic pig model显示文摘	Laurenz J C Collier C C Kuti J O	2003	Phytother Res2003，17，1：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示